ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
19 announcements with these filters
Link Pharma Chem Ltd filed a periodic non-applicability notice for Reg 23(9) RPT disclosure. The company's paid-up capital and net worth fall below LODR thresholds, so no disclosure is required.
Link Pharma Chem approved unaudited results for the quarter and half year ended 30 September 2026. Revenue was Rs.533.13 Lakh with a loss of Rs.22.31 Lakh for the quarter.
Link Pharma Chem's board meets on 3 November 2026 to approve unaudited half-year results. The trading window stays closed until results are declared.
Link Pharma Chem Ltd has filed its quarterly shareholding pattern as mandated by SEBI regulations. This routine disclosure provides the updated ownership structure for the company.
Link Pharma Chem Ltd received a GST order reducing the total demand and penalty for FY 2021-22. The company plans to appeal the decision.
Link Pharma Chem Limited has announced the re-appointment of Rishikesh Thakur and Satish G Thakur as Executive Directors for a term of 36 months each.
Link Pharma Chem Ltd. held its 41st Annual General Meeting on August 20, 2026, where shareholders transacted various ordinary and special business items.
Link Pharma Chem Ltd reported revenue from operations of ₹8.8 Cr (+12.8% YoY) and net profit of ₹0.3 Cr (-25.0% YoY) for Q1 FY27.
Link Pharma Chem Ltd notified the exchange regarding the dispatch of letters to shareholders containing the web link for the Annual Report 2025-2026.
Link Pharma Chem Ltd has scheduled a board meeting for August 5, 2026. The board will consider and approve unaudited financial results for the quarter ended June 30, 2026.
Link Pharma Chem Ltd has issued a notice convening its 41st Annual General Meeting on August 20, 2026, to be held via video conferencing.
Link Pharma Chem disclosed an inter-se transfer of 92,808 shares among promoter group members due to family succession in its shareholding pattern filing.
Link Pharma Chem confirms non-applicability of SEBI's Related Party Transaction disclosure requirements. The company remains below prescribed paid-up capital and net worth thresholds for compliance.
Link Pharma Chem approved the re-appointment of Mr. Satish G. Thakur as Chairman and Whole-time Director. His three-year term commences on June 24, 2026.
Link Pharma Chem Ltd reported audited financial results for the year ended March 31, 2026. The Board also approved several key auditor and director re-appointments.
Link Pharma Chem Ltd reported revenue from operations of ₹6.6 Cr (+3.1% YoY) and a net loss of ₹0.4 Cr for Q4 FY26.
Link Pharma Chem reported total annual income of ₹27.63 Crore and net profit of ₹0.08 Crore. The board also approved re-appointing key directors for three-year terms.
Link Pharma Chem scheduled a board meeting for May 21, 2026, to approve audited annual financial results. The trading window remains closed until May 23.
Link Pharma Chem Ltd submitted its quarterly confirmation certificate under Regulation 74(5) of SEBI (DP) Regulations for the period ended March 31, 2026. The certificate, issued by MUFG Intime India, confirms the processing of dematerialisation requests and substitution of names in the register of members within prescribed timelines.